2. Signaling Pathways
  3. PROTAC
  4. Ligands for Target Protein for PROTAC

Ligands for Target Protein for PROTAC

Target Protein-binding Moiety

Ligands for Target Protein for PROTAC

Related Products

PDF 0.95 MB

The PROTAC molecule consists of a target protein ligand and an E3 ubiquitin ligase ligand, with a linker binds them together. The ligand for target protein will lead to attachment of a PROTAC to the proteins of interest for ubiquitin and subsequent degradation.

Target proteins are usually proteins whose overexpression or accumulation may play important roles in the progress of diseases. Numbers of PROTACs have been developed to degrade kinases (such as MEK, KRAS, CDK and Bcr/Abl), transcription factors (such as p53, STAT, RAR, ER and AR), epigenetic tools (such as HDAC and BET bromodomain) and E3 ligase themselves (such as MDM2).

Ligands for Target Protein for PROTAC Related Products (512):

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-159662
    HSD17B13 degrader 2 3035000-69-9
    HSD17B13 degrader 2 is a PROTAC target protein ligand (Ligands for Target Protein for PROTACs). HSD17B13 degrader 2 can be used for synthesis PTOTAC HSD17B13 degrader 1 (HY-159651).
    HSD17B13 degrader 2
  • HY-173067
    IDO1 ligand-1 3048196-74-0
    IDO1 ligand-1 is the target protein ligand of PROTAC NU227326 (HY-173066). NU227326 can be used to degrade IDO1.
    IDO1 ligand-1
  • HY-174314
    WZH-15-125 2845188-22-7
    WZH-15-125 is a potent ALK inhibitor. WZH-15-125 can effectively overcome drug resistance, especially compound ALK mutations. WZH-15-125 has an IC50 of 101.7 nM for the highly refractory G1202R/L1196M mutation that is resistant to Lorlatinib (HY-12215). WZH-15-125 can be used as a PROTAC target protein ligand to synthesize PROTAC WZH-17-002 (HY-174315). WZH-15-125 can be used in the research of non-small cell lung cancer.
    WZH-15-125
  • HY-181790
    DOT1L ligand-2
    DOT1L ligand-2 (Compound 52) is a DOT1L ligand. DOT1L ligand-2 acts as a Ligand for Target Protein for PROTAC, which is used to develop and design degraders of PROTAC DOT1L, such as DOT1L808 (HY-181789). DOT1L ligand-2 is applicable to research related to MLL-rearranged leukemia.
    DOT1L ligand-2
  • HY-177016
    LRRK2-IN-19 2839667-09-1
    LRRK2-IN-19 is a PROTAC target protein ligand that can be used to synthesize PROTAC JH-XII-03-02 (HY-155150). JH-XII-03-02 is a highly potent and selective LRRK2 PROTAC degrader, which can be used in Parkinson's disease research.
    LRRK2-IN-19
  • HY-169073
    TC13172-NH-COOH
    TC13172-NH-COOH is a PROTAC target protein ligand (Ligands for Target Protein for PROTACs). TC13172-NH-COOH can be used for synthesis PROTAC MLKL Degrader-2 (HY-169072).
    TC13172-NH-COOH
  • HY-153718
    KI-ARv-03 2416873-72-6
    KI-ARv-03 is a potent and selective ATP-competitive CDK9 inhibitor with an IC₅₀ of 0.15 μM (at 45 μM ATP), exhibiting over 130-fold selectivity against other CDKs (including CDK1-7). KI-ARv-03 reduces androgen receptor (AR)-driven transcription and proliferation in prostate cancer cells. KI-ARv-03 can be used for leukemia, pancreatic cancer, alveolar rhabdomyosarcoma (ARMS) and castration-resistant prostate cancer (CRPC) research. KI-ARv-03 is a ligand for target protein for PROTAC. KI-ARv-03 can be used to synthesize PROTAC KI-CDK9d-32 (HY-173523)[1][2].
    KI-ARv-03
  • HY-181904
    SARS-CoV-2 Mpro ligand 2
    SARS-CoV-2 Mpro ligand 2 (Compound 24) is a ligand for the target protein for PROTAC (SARS-CoV-2 Mpro). SARS-CoV-2 Mpro ligand 2 can be used to synthesize PROTAC SARS-CoV-2 Mpro degrader-8 (HY-181870).
    SARS-CoV-2 Mpro ligand 2
  • HY-174471
    HDAC-IN-90 1354547-28-6
    HDAC-IN-90 is the ligand for HDAC6/10 that can be used for synthesis of PROTAC HDAC degrader-2 (HY-174444).
    HDAC-IN-90
  • HY-176795
    SHP2 ligand-3 2624181-60-6
    SHP2 ligand-3 is a PROTAC target protein ligand that can be used to synthesize SHP2 protein degrader-1 (HY-145159).
    SHP2 ligand-3
  • HY-176467
    TAF1 ligand 1 1926986-25-5
    TAF1 ligand 1 is a TAF1 ligand. TAF1 ligand 1 can be used as a Ligands for Target Protein for PROTAC synthesis, such as ZS3-046 (HY-176457).
    TAF1 ligand 1
  • HY-184259
    PTPN2 ligand 4
    PTPN2 ligand 4 is a PTPN2 ligand and can be used for the synthesis of PROTACs, such as PD-305 (HY-183937).
    PTPN2 ligand 4
  • HY-163852
    HIV-1 inhibitor-72 2801703-79-5
    HIV-1 inhibitor-72 (compound 5m) is a target protein ligand of PROTAC Vif degrader-1 (HY-163851). HIV-1 inhibitor-72 is a potent HIV-1 inhibitor.
    HIV-1 inhibitor-72
  • HY-168638
    PROTAC SOS1 ligand 1 3027977-34-7
    PROTAC SOS1 ligand 1, a BI-3406 (HY-125817) analog, is a ligand for target SOS1 protein for PROTACT SIAIS562055 (HY-168637).
    PROTAC SOS1 ligand 1
  • HY-131559
    N-Deacetyl-SI-109-(OEt)2 2429878-64-6
    N-Deacetyl-SI-109-(OEt)2 (Compound 11) is a STAT3 ligand. N-Deacetyl-SI-109-(OEt)2 serves as a Ligand for target protein for the synthesis of STAT3 PROTAC degraders, such as SD-36 (HY-129602). N-Deacetyl-SI-109-(OEt)2 is applicable for cancer research.
    N-Deacetyl-SI-109-(OEt)2
  • HY-179051
    PSMA ligand 3 2756661-48-8
    PSMA ligand 3 is a PSMA-targeting ligand of Psa-AR (HY-179056). Psa-AR can be used for cancer research.
    PSMA ligand 3
  • HY-180484
    PKMYT1-IN-12 2974454-59-4
    PKMYT1-IN-12 (Compound 4) is a selective inhibitor of PKMYT1, with an IC₅₀ of 2.6 nM. PKMYT1-IN-12 can effectively inhibit the phosphorylation of CDK1, with an IC₅₀ of 44 nM. PKMYT1-IN-12 is a target protein ligand that can be used for the synthesis of PROTAC D16-M1P2 (HY-180485).
    PKMYT1-IN-12
  • HY-176825
    MU1742-amide-C6-acid
    MU1742-amide-C6-acid is a CK1δ/ε inhibitor. MU1742-amide-C6-acid can be used for synthesis of PROTAC AH081 (HY-170859A).
    MU1742-amide-C6-acid
  • HY-160094
    BCN-sulfonamide-PEG2-sulfonamide-N-bis(ethanol) 2126749-81-1
    BCN-sulfonamide-PEG2-sulfonamide-N-bis ethanol (compound 71) is a Ligands for Target Protein for PROTAC that contains a sulfonamide linker to increase the solubility of the linker-conjugate. BCN-sulfonamide-PEG2-sulfonamide-N-bis ethanol can be used to synthesize PROTACs with antitumor activity.
    BCN-sulfonamide-PEG2-sulfonamide-N-bis(ethanol)
  • HY-169180
    AK-068-OH 2982851-61-4
    AK-068-OH (Compound 49) is an active control of ligand for target protein for PROTAC (HY-169179).
    AK-068-OH